Skip to content

Study · Not a test of the peptide alone · 1996

3 results

Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity.

Haskell-Luevano C, Sawyer TK, Hendrata S, North C, Panahinia L, Stum M, Staples DJ, Castrucci AM, Hadley MF, Hruby VJ

Peptides1 Jan 1996Cited by 55 (Europe PMC)

PMID8899819 (opens in a new tab)DOI10.1016/0196-9781(96)00141-6 (opens in a new tab)PepBankPUB-08899819
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In the frog skin assay, tripeptide fragments derived from NDP-MSH showed prolonged agonist bioactivity.

    In plain wordsIn lab tests on frog skin, short pieces of NDP-MSH kept their pigment-darkening activity for a prolonged time.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableProlonged bioactivity of tripeptide agonists
    Study

    frogn: not reported in source

    frog skin assay
    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    Ac-Ser.Tyr-Ser-Nle4-Glu- His-DPhe7-Arg-Trp-Gly-Lys-Pro-Val-NH2(NDP-MSH), led to the discovery of tripeptide agonists possessing prolonged bioactivity in the frog skin assay.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    Ac-DPhe-Arg-DTrp-NH2 was the most potent tripeptide of the series and showed sustained melanotropic activity in the frog skin assay.

    In plain wordsIn lab tests on frog skin, one short NDP-MSH fragment was the most potent of the series and kept its activity.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePotency of Ac-DPhe-Arg-DTrp-NH2
    Study

    frogn: not reported in source

    frog skin assay
    Outcome group
    Pigmentation · Skin and wound

    Source sentences

    Summary
    Of particular significance to this discovery was Ac-DPhe-Arg-DTrp-NH2, which was the most potent tripeptide in this series exhibiting sustained melanotropic activity.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueMechanism

    Three tripeptide stereochemical combinations require only Phe7-Xaa8-Trp9, whereas three others additionally require His4 for minimal biological activity.

    In plain wordsIn lab tests, some short fragments need only three amino acids to work. Others also need a fourth.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableMinimal sequence requirement for tripeptide activity
    Study

    frogn: not reported in source

    frog skin assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The tripeptides Ac-DPhe-Arg-Trp-NH2, Ac-DPhe-Arg-DTrp-NH2, and Ac-DPhe-DArg-Trp-NH2 stereo-chemical combinations require only Phe7-Xaa8-Trp9, whereas Ac-DPhe-DArg-DTrp-NH2, Ac-Phe-Arg-DTrp-NH2, and Ac-Phe-Arg-Trp-NH2 additionally require His4 for minimal biological activity.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.